After years of price pressures, the trade group argues “the economics of generics have deteriorated to the point where ...
This guide explores the evolving role of podcasts, webinars, and thought leadership programs in biopharma and provides ...
BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...
SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...
Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the ...
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall ...
A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved ...
As of the data cutoff on August 20, 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming ...
A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ...
ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically meaningful 2.2-point improvement in motor function as ...
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc.
With oral cyclic peptides offering small molecule convenience and antibody‑like selectivity, the modality is gaining momentum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results